BusinessFederman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Antares Pharma, Inc.By Nasdaq OMXOct 25, 2017, 7:47 PM UTC
BusinessNeos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years OldBy Nasdaq OMXJun 20, 2017, 1:47 AM UTC
BusinessNeos Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare ConferenceBy Nasdaq OMXFeb 16, 2017, 12:30 PM UTC
BusinessNeos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHDBy Nasdaq OMXDec 20, 2016, 12:30 PM UTC
